Justice GCC
ar ع
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
Reading: UAE Regulator First to Clear New Ultomiris Use for Proteinuria in Immune Kidney Disease
Share
Justice GCCJustice GCC
Font ResizerAa
  • Legislation
  • Courts
  • Law Firms
  • Deals
Search
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC > Legislation > UAE Regulator First to Clear New Ultomiris Use for Proteinuria in Immune Kidney Disease
Legislation

UAE Regulator First to Clear New Ultomiris Use for Proteinuria in Immune Kidney Disease

NewsDesk
Last updated: November 10, 2026 4:24 pm
NewsDesk
Share
UAE Approves Ultomiris for Kidney Disease | AI-Generated Image
SHARE

The Emirates Drug Establishment announced the conditional approval for the new use of Ultomiris, also known as ravulizumab, which is intended for adults with primary immunoglobulin A nephropathy who face a high risk of disease worsening. This intravenous therapy aims to lower protein levels in the urine, a key sign of advancing kidney damage, according to the regulator’s statement. The decision follows the medicine’s initial registration in the UAE in 2022 for multiple rare diseases, expanding its available indications in the country.

Primary immunoglobulin A nephropathy is an immune-mediated condition that develops when immune proteins accumulate in kidney tissue, triggering inflammation and a gradual loss of function, a review in Seminars in Nephrology described. The disease carries a global incidence of roughly 2.5 cases per 100,000 people each year, though biopsy data show it accounts for between 25 and 50 percent of primary glomerular disease cases across East Asian countries while remaining less frequent in North America and Africa. Elevated urinary protein serves as a major predictor of progression toward more severe outcomes including potential kidney failure, the Emirates Drug Establishment noted.

Interim results from the I CAN Phase 3 trial, published in the New England Journal of Medicine, found that Ultomiris delivered a 46.6 percent drop in the 24-hour urine protein-to-creatinine ratio at week 34 from baseline compared with a 5.6 percent reduction in the placebo arm. This produced a 43.4 percent placebo-adjusted advantage, with benefits emerging by week 10 and holding steady through the assessment period across varied patient subgroups. Safety data indicated adverse events in 69.5 percent of those receiving Ultomiris versus 75.8 percent on placebo, with no meningococcal infections or fatalities recorded in either group.

Dr Ruqaya Al Bastaki, acting executive director of the medical products regulation sector at the Emirates Drug Establishment, stated that the body’s evaluation process rests on detailed scientific review while maintaining stringent standards for safety, quality and effectiveness. The Emirates Drug Establishment emphasised the value of prompt diagnosis together with consistent tracking of kidney performance and urinary protein alongside strict compliance with physician-directed regimens to limit complications. Such measures form part of a broader effort to address this form of kidney disease effectively in clinical practice.

Sameh El Fangary, Gulf Cluster President at AstraZeneca, described the conditional approval as a meaningful advance that broadens therapeutic choices for individuals living with immunoglobulin A nephropathy. He indicated that the company anticipates ongoing cooperation with UAE authorities to facilitate access for suitable patients, enhance clinical results and raise overall standards of care, according to the announcement. The conditional status requires continued evidence gathering to affirm sustained benefits under real-world conditions.

This regulatory action supports the objectives of the We the UAE 2031 vision by reinforcing the nation’s standing in healthcare and pharmaceutical innovation while promoting research and development, the Emirates Drug Establishment said in its statement. It also advances the establishment’s goal of building a forward-looking regulatory environment that draws on international best practices to accelerate availability of new therapies without compromising quality. The Emirates Drug Establishment first registered Ultomiris in 2022, providing a foundation for this latest expansion in approved uses.

Share This Article
Email Copy Link Print
ByNewsDesk
Justice GCC NewsDesk is the desk responsible for Justice GCC's daily news coverage, monitoring and reporting developments across the Gulf from official sources, including national news agencies and government communications. Its focus is accurate, timely and factual coverage of the region.
Previous Article UAE First to Conditionally Approve New Use of Ultomiris for Immune-Mediated Kidney Disease
Next Article Capmont Acquires Majority Stake in Germany’s Kramer Group in Founder Succession Deal

Popular Posts

Saudi Court Sentences Kenyan Migrant Worker to 100 Lashes for Extramarital Birth

A Saudi court sentenced Kenyan domestic worker Esther Wanja Muthoni to 100 lashes after she gave birth outside marriage in…

By
NewsDesk
3 Min Read
Emirates Drug Establishment First to Approve Ultomiris for Proteinuria in IgA Nephropathy

The Emirates Drug Establishment granted conditional approval on November 10, 2026 for…

5 Min Read
Baker McKenzie Recruits Data Protection Expert Kelly Hagedorn in London Lateral Move

Baker McKenzie announced the appointment of Kelly Hagedorn as a cybersecurity and…

3 Min Read

More News

Qatar Denounces Iranian Strikes on Kuwait and Bahrain as Breaches of Sovereignty

Qatar's Ministry of Foreign Affairs condemned renewed Iranian attacks on…

November 18, 2026

VAT Group Closes Atonarp Acquisition Financed by CHF 110 Million Bilateral Loan

VAT Group completed the acquisition of…

November 18, 2026

Natroshvili Expands Business Portfolio With UAE Legal Advisory Launch

David Natroshvili, ranked the most influential…

November 17, 2026

Iran Condemns Bahrain’s Life Sentences for Shia Clerics as Rights Abuse

Iran's Foreign Ministry on November 17,…

November 17, 2026

Bahraini Court Sentences 64 to Life in Prison Over Alleged Iran Links

A Bahraini court on November 16…

November 17, 2026

Recommended for You

Legislation

Kuwait Repeals Capital Markets Court in Decree-Law 91 and Shifts Non-Criminal Disputes to Economic Circuits

Kuwait published Decree-Law No. 91 of 2026 this week abolishing the Capital Markets Court framework and transferring non-criminal securities disputes…

4 Min Read
Legislation

GCC States Propose Framework to Counter Maritime Threats and Protect Key Shipping Routes

GCC member states announced a draft resolution on April 16, 2026, establishing a cooperative framework to strengthen maritime security, protect…

3 Min Read
Legislation

Community Reporting Helps Explain National Changes to Kuwait’s Diverse Residents

On October 3, 2026, Times Kuwait argued that community journalism plays a key role in a rapidly evolving society where…

3 Min Read
Legislation

Bahrain Enacts Framework for Security Over Movable Assets to Widen Finance Access

Bahrain published its Secured Transactions Law No. 3 of 2026 on Jan. 29 in the Official Gazette, introducing rules that…

3 Min Read

Categories

  • Legislation
  • Courts
  • Law Firms
  • Deals

Quick Links

  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC
© 2026 Justice GCC. Published by Peninsula News Group LLC. All rights reserved.
  • Privacy Policy
  • Terms of Use
  • Contact
Welcome to Foxiz

Sign in to your account

Username or Email Address
Password

Lost your password?